A concerning development in gene therapy research has emerged with the discovery that adeno-associated virus (AAV) vectors, widely considered among the safest gene delivery systems, may pose previously unrecognized cancer risks when delivered directly to the brain. This finding challenges the field's confidence in AAV-based treatments for neurological disorders and could reshape clinical trial protocols worldwide. The case involves a patient who developed a neuroepithelial brain tumor following intracisternal administration of AAV vectors, with molecular analysis confirming viral DNA integration at the tumor site. This delivery method bypasses the blood-brain barrier by injecting therapeutic vectors directly into cerebrospinal fluid, a technique increasingly used for treating pediatric neurological conditions. The integration pattern suggests the AAV vector inserted into chromosomal DNA near genes involved in cell growth regulation, potentially triggering malignant transformation. While AAV vectors have historically shown minimal integration compared to other gene therapy vehicles like retroviruses, this incident reveals that direct central nervous system delivery may create different risk profiles than peripheral administration. The implications extend beyond this single case, as dozens of AAV-based neurological therapies are currently in clinical development. The gene therapy community now faces difficult questions about risk-benefit calculations, particularly for pediatric patients with degenerative conditions where treatment urgency often outweighs theoretical long-term risks. This development mirrors earlier setbacks in gene therapy history, though AAV's generally superior safety profile means immediate halts to ongoing trials are unlikely. Instead, enhanced monitoring protocols and refined vector designs will likely emerge. The finding underscores the critical importance of long-term follow-up in gene therapy patients and may accelerate research into next-generation vectors with reduced integration potential.